RPE65 and Leber congenital amaurosis: The 2017 FDA approval of LUXTURNA (voretigene neparvovec‐rzyl), a subretinally delivered AAV therapeutic for the treatment of the inherited retinal disorder Leber congenital amaurosis (LCA) type‐2, has shown the feasibility of viral‐mediated total gene replacement therapy for RPE65 (retinal pigment epithelial‐specific 65 kDa protein).